Inner Mongolia Furui Medical Science 福瑞医科
4 significant filings since 30 May 2026: 1 on major holder selling, 1 on dividend and 1 on equity incentive, and 1 other kind. The latest, on 7 Sep 2026: 关于实际控制人减持股份的预披露公告.
自 30 May 2026 起有 4 份重大公告：major holder selling 1 份、dividend 1 份、equity incentive 1 份，另有 1 类。最新一份（7 Sep 2026）：关于实际控制人减持股份的预披露公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 13 Sep 2024 | 国信证券 | 张佳博 | Buy 买入 | ▼ | Outperform 增持 |
| 9 Aug 2021 | 西南证券 | 杜向阳 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳,雷瑞 | Unrated | 31 Mar 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。